Major Depressive Disorder
Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every day; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
Drugs by status
Approved for this indication (30)
- brexpiprazole
- paroxetine
- citalopram
- valproic acid
- duloxetine
- selegiline
- escitalopram
- sertraline
- triacetylglycerol
- esketamine
- isocarboxazid
- fluoxetine
- nefazodone
- olanzapine
- risperidone
- desvenlafaxine
- tranylcypromine
- trazodone
- vilazodone
- vortioxetine
- bupropion
- venlaxafine
- aripiprazole
- quetiapine
- mirtazapine
- gepirone monohydrochloride
- venlafaxine
- maprotiline
- levomilnacipran
- oxitriptan
Phase 4 trials (70)
- nitrous oxide
- simvastatin
- sarcosine
- acamprosate
- agomelatine
- buspirone
- cariprazine
- lamotrigine
- ketamine
- clozapine
- methylphenidate
- progesterone
- suvorexant
- escalitopram
- fluvoxamine
- fremanezumab
- naltrexone
- guanfacine
- iloperidone
- imipramine
- etomidate
- levodopa
- carbidopa
- lithium
- succinylcholine
- 11c dasb
- valsartan
- nicotine
- ramelteon
- tizanidine
- +40 more
Phase 3 trials (47)
- roflumilast
- mifepristone
- lurasidone
- samidorphan
- lysergic acid diethylamide
- amibegron
- amitriptyline
- deuterated dextromethorphan
- ibuprofen
- dexmecamylamine
- amitifadine
- ziprasidone
- liraglutide
- rapastinel
- rosuvastatin
- insulin human
- icosapent ethyl
- idazoxan
- edivoxetine
- memantine
- pipamperone
- dextromethadone
- zuranolone
- Ulotaront
- tasimelteon
- anyu peibo
- bifidobacterium longum
- human fecal microbiota
- lactobacillus helveticus
- modafinil
- +17 more
Phase 2 trials (126)
- metformin
- melatonin
- maltodextrin
- thk-5351
- nsi-189
- florbetapir
- abt-436
- triphosphoric acid adenosine ester
- mecamylamine
- l-4-cl-kyn
- azd-2066
- azd7268
- basimglurant
- Coluracetam
- Casopitant
- cerc-301
- tadalafil
- clavulanate
- clobetasol
- lipopolysaccharide
- Antalarmin
- cp-601927
- centanafadine
- cycloserine
- perampanel
- empagliflozin
- cannabidiol
- ezogabine
- palmitoylethanolamide
- isoflurane
- +96 more
Phase 1 trials (40)
- propofol
- ketoprofen
- ucb-j
- Rolipram
- tibolone
- oxytocin
- theophylline
- acetylcysteine
- medicinal charcoal
- diphenhydramine
- ethanol
- ethinyl estradiol
- zopiclone
- gsk163090
- warfarin
- xenon-129
- nitrogen
- lorazepam
- ansofaxine
- moclobemide
- propranolol
- digoxin
- salmonella typhi vaccine
- amisulpride
- albuterol
- clarithromycin
- norgestimate
- clopidogrel
- liothyronine
- codeine
- +10 more
Other trials (43)
- ringer's lactate
- urea
- golimumab
- d-serine
- folic acid
- ganaxolone
- gelatin
- sevoflurane
- ginseng
- goserelin
- calcium
- sodium oxybate
- soybean oil
- cabergoline
- methohexital sodium
- bromocriptine
- ribavirin
- sorbitol
- bevacizumab
- bifidobacterium infantis
- bifidobacterium breve
- curcumin
- inactivated influenza vaccine
- lactobacillus plantarum
- lycium barbarum
- lexipro
- cilostazol
- sildenafil
- insulin lispro
- pregabalin
- +13 more
Organizations
Organization Involved with Phase 4 Indications (167)
- the First Specialized Subject Hospital of Harbin
- State University of New York, Buffalo
- National Institutes of Health (NIH)
- University of Saskatchewan
- People's Liberation Army of China
- Columbia University
- ElMindA Ltd
- Teva
- University of Missouri
- Medtronic
- Duke University
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Cincinnati
- University of Oxford
- Chokka Center for Integrative Health
- Ganeden Biotech, Inc.
- Thomas Jefferson University
- Alto Neuroscience
- Seoul National University
- Tufts University
- The Medical Research Network, LLC
- Shanxi Medical University
- University of Michigan
- Government of Canada
- University of California, Los Angeles
- Orebro University
- Research Foundation for Mental Hygiene, Inc.
- University of Alabama, Birmingham
- Cognitive Research Corporation
- Brain & Behavior Research Foundation
- +137 more
Organization Involved with Phase 3 Indications (69)
- University of Grenoble
- Genaissance
- Pakistan Institute of Living and Learning
- Gedeon Richter Ltd.
- National Center for Complementary and Integrative Health (NCCIH)
- Zentrum für Integrative Psychiatrie
- Acadia Pharmaceuticals
- Hemanny, Curt, M.D.
- University of Rochester
- Lund University
- Brown University
- Su Zhou YiHua Biotechnology Co. LTD
- Centre Hospitalier Universitaire de Nīmes
- Axsome Therapeutics, Inc.
- Dalhousie University
- Hebrew University
- Bayer
- Midwest Clinical Research Center, Ohio
- University of Hamburg
- Isfahan University
- Shijiazhuang Pharma Group (CSPC)
- The Royal's Institute of Mental Health Research
- Relmada Therapeutics, Inc.
- PharmaNeuroBoost N.V.
- Ruhr University Bochum
- University of Nimes
- Case Western Reserve University
- McGill University
- University of North Carolina at Chapel Hill
- Labopharm
- +39 more
Organization Involved with Phase 2 Indications (95)
- Epix Pharmaceuticals
- Maryland Oncology Hematology, PA
- Sphere Healthcare
- Karolinska Institute
- Clinilabs
- University of Chicago
- University of Zurich
- Boston Clinical Trials
- Jinlin University
- CNS Healthcare
- University of Minnesota
- Hospital de Sant Pau i Santa Tecla de Tarragona
- FGK Clinical Research GmbH
- Ciusss de L'Est de l'Île de Montréal
- BrainCells Inc.
- University of New South Wales
- Artemis Institute for Clinical Research
- Comprehensive Psychiatric Care, Norwich CT
- DOV Pharmaceutical, Inc.
- University of Queensland
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- University of Connecticut
- AlzChem AG
- University of Texas at Houston
- Section for Affective Disorders; Northern Stockholm Psychiatry
- Sadat City University
- NuBiyota
- e-Therapeutics PLC
- BioLite, Inc.
- heckel medizintechnik GmbH
- +65 more
Organization Involved with Phase 1 Indications (34)
- Central Visitation, Region Hovedstaden
- Trinity College Dublin
- Luye Pharma
- Wenzhou Medical University
- Beijing Winsunny Pharmceutical Co.,Ltd.
- Abbott
- Algorithme Pharma Inc
- Mayo Clinic
- Harbin Medical University
- Pharmaceutical Research Associates, Inc. (PRA)
- IQVIA
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Kufa University
- University of Stavanger
- Wuhan Psychiatric Hospital
- Medical University of Vienna
- Assiut University
- The Pittsburgh Foundation
- Gate Neurosciences, Inc
- Chongqing Medical University
- Affective Neuroscience Laboratory
- Comprehensive Clinical Development, Inc.
- Anhui Medical University
- Taipei Veteran General hospital
- Medical University of South Carolina
- Chicago Research Center, Inc.
- National Network of Depression Centers
- Heffter Research Institute
- University of Iowa
- Suven Life Sciences Limited
- +4 more
Organization Involved with Other Experimental Indications (52)
- Aarhus University
- Dalian Seventh People's Hospital
- The Nazareth Hospital, Israel
- Chhatrapati Sahuji Maharaj Medical University
- Xijing Hospital
- Government of China
- Sir T. General Hospital and Government Medical College
- Ryerson University
- Taichung Veterans General Hospital
- Bangladesh Medical University
- The Korean Society of Ginseng
- Technion University
- Max Planck Institute
- Aga Khan University
- Hennepin Healthcare
- NeuroCure Clinical Research Center
- University of Salerno
- Showa University
- King Edward Medical University
- China Academy of Chinese Medical Sciences
- Universidad Autonoma de Nuevo Leon
- University of Turku
- Instituto de Información e Investigación en Salud Mental A. C.
- Aalborg University
- Arjuna Natural Extracts Ltd.
- EMDR Europe
- Tvergaards Foundation
- Government Medical College, Bhavnagar
- Sichuan University
- Hebei University
- +22 more